Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017

Terpos, Evangelos

doi:10.1016/j.clml.2018.02.015

Cited by 16 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have compared transplantation with novel agents in order to avoid the cytotoxicity associated with high dose melphalan. These studies have confirmed the place of transplantation a beneficial procedure, showing improved progression‐free survival and higher rates of MRD …”

Section: Transplant‐eligible Patientsmentioning

confidence: 62%

“…Patients are enrolled to receive maximal therapy with the newest available agents, including carfilzomib, and ongoing lenalidomide maintenance. Treatment in this trial has shown high remission rates, with 85% of patients who completed therapy remaining progression‐free . However, overall survival data are still awaited but crucial to confirm the value of treatment in an asymptomatic phase.…”

Section: Diagnosis: Smouldering Multiple Myeloma and Active Myelomamentioning

confidence: 88%

“…A large clinical trial in the United Kingdom has shown that prophylactic levofloxacin given for the first 12 weeks of therapy reduces the incidence of infections during the induction phase of the therapy . The routine use of antiviral agents has significantly lessened the incidence of herpes zoster, especially in patients treated with proteasome inhibitors.…”

Section: Supportive Therapiesmentioning

confidence: 99%

See 2 more Smart Citations

Biology and therapy of multiple myeloma

Joshua

Bryant

Dix

et al. 2019

Medical Journal of Australia

View full text Add to dashboard Cite

Summary Genetic sequencing of the myeloma genome has not revealed a specific disease‐determining genetic alteration. Multiple disease subclones exist at diagnosis and vary in clinical importance with time and drug sensitivity. New diagnostic criteria have identified indications for early introduction of therapy. Autologous stem cell transplantation remains an essential component of therapy in young and fit patients. The use of continual suppressive (maintenance) therapy has been established as an important component in therapy. Immune therapies and the harnessing of the innate immune system offer great promise for future treatments. Since 2005, quality of life, supportive therapies, and survival have dramatically improved over a decade of remarkable progress. The common manifestations of multiple myeloma, such as bone pain, fatigue and weight loss, may be non‐specific and are often initially ignored or missed by patients and medical practitioners.

show abstract

Section: Transplant‐eligible Patientsmentioning

confidence: 62%

Section: Diagnosis: Smouldering Multiple Myeloma and Active Myelomamentioning

confidence: 88%

Section: Supportive Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Biology and therapy of multiple myeloma

Joshua

Bryant

Dix

et al. 2019

Medical Journal of Australia

View full text Add to dashboard Cite

show abstract

“…Recently, the introduction of the next-generation PI, carfilzomib, in the induction regimens has been evaluated [60]. The combination of carfilzomib-lenalidomide-dexamethasone (KRD) has shown early responses and ORR rates reaching 95%, including a more than 20% CR or better rate [61,62].…”

Section: Optimizing Induction Regimensmentioning

confidence: 99%

Multiple myeloma: Role of autologous transplantation

Ntanasis‐Stathopoulos¹,

Gavriatopoulou²,

Kastritis

et al. 2020

Cancer Treatment Reviews

Self Cite

View full text Add to dashboard Cite

“…Generally, cyclophosphamide or melphalan are utilized for the treatment of multiple myeloma in combination with intravenous bisphosphonates that reduce the risks of skeletal complications [9]. The use of cyclophosphamide or melphalan in combination with prednisone, thalidomide, bortezomib, or carfilzomib was introduced as the major treatment regimens for multiple myeloma in 2016 [8], whereas at the 2017 American Society of Hematology Annual Meeting, the use of cyclophosphamide and melphalan were reportedly decreased [10]. Different doses of cyclophosphamide are administered to multiple myeloma patients depending on the patient's age and tolerability [9].…”

Section: Introductionmentioning

confidence: 99%

Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice

Kuroshima

Sasaki

Nakajima

et al. 2018

Bone

View full text Add to dashboard Cite

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) worsens oral health-related quality of life. Most BRONJ occurs in multiple myeloma or metastatic breast cancer patients treated with bisphosphonate/chemotherapeutic combination therapies. Cyclophosphamide (CY), an alkylating chemotherapeutic drug, is used to treat multiple myeloma, although its use has been recently reduced. The aim of this study was to clarify the effects of CY dose on tooth extraction socket healing when CY is used with or without bisphosphonate in mice. Low-dose CY (50 mg/kg; CY-L), moderate-dose CY (100 mg/kg; CY-M), high-dose CY (150 mg/kg; CY-H), and bisphosphonate [Zometa (ZA): 0.05 mg/kg] were administered for 7 weeks. Each dose of CY and ZA in combination was also administered for 7 weeks. Both maxillary first molars were extracted at 3 weeks after the initiation of drug administration. Euthanasia was performed at 4 weeks post-extraction. Gross wound healing, microcomputed tomography analysis, histomorphometry, and immunohistochemistry were used to quantitatively evaluate osseous and soft tissue wound healing of tooth extraction sockets. ZA monotherapy induced no BRONJ-like lesions in mice. CY monotherapy rarely induced open wounds, though delayed osseous wound healing occurred in a CY dose-dependent manner. In contrast, CY/ZA combination therapy prevalently induced BRONJ-like lesions with compromised osseous and soft tissue healing in a CY dose-dependent manner. Interestingly, anti-angiogenesis was noted regardless of CY dose and ZA administration, even though only CY-M/ZA and CY-H/ZA combination therapies induced BRONJ-like lesions. Our findings suggest that high-dose CY may be associated with the development of BRONJ following tooth extraction only when CY is used together with ZA. In addition to anti-angiogenesis, other factors may contribute to the pathoetiology of BRONJ.

show abstract

Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017

Cited by 16 publications

References 21 publications

Biology and therapy of multiple myeloma

Biology and therapy of multiple myeloma

Multiple myeloma: Role of autologous transplantation

Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice

Contact Info

Product

Resources

About